Results 11 to 20 of about 141,900 (251)

Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome [PDF]

open access: yesHuman Reproduction, 2017
STUDY QUESTION: Would letrozole as a primary ovulation induction agent generate better pregnancy rates than clomiphene citrate (CC) in subfertile women with anovulatory polycystic ovarian syndrome (PCOS)? SUMMARY ANSWER: Participants receiving letrozole
Amer, Saad A.   +4 more
core   +3 more sources

Clomiphene citrate: A potential alternative for testosterone therapy in hypogonadal males. [PDF]

open access: yesEndocrinol Diabetes Metab, 2023
Hypogonadism is a worldwide problem among men causing sexual, physical and mental problems. Testosterone therapy is the first‐choice treatment for male hypogonadism, with several side effects, that is, subfertility.
Huijben M   +5 more
europepmc   +2 more sources

A Case of Ethmocephaly in a Clomiphene Citrate Induced Pregnancy: A Case Report and Literature Review. [PDF]

open access: yesClin Case Rep
Clinical image of the newborn displaying hypotelorism with proboscis (arrow) and absent nasal structure. ABSTRACT Ethmocephaly is the most severe form of holoprosencephaly, which results from incomplete cleavage of the forebrain during embryogenesis. It is incompatible with life.
Negasi Gebreslase M   +7 more
europepmc   +2 more sources

Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. [PDF]

open access: yesPharmaceuticals (Basel)
Male hypogonadism, which is characterized by low testosterone levels, has a significant impact on male sexual function, overall health, and fertility.
Wu YC, Sung WW.
europepmc   +2 more sources

Clomiphene citrate for male infertility: A systematic review and meta‐analysis

open access: yesAndrology, 2023
Male infertility is a prevalent and worldwide problem with various difficulties in treatment. Clomiphene citrate is a selective estrogen receptor modulator and may improve semen quality by stimulating hormone synthesis and spermatogenesis.
M. Huijben   +5 more
semanticscholar   +1 more source

Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

open access: yesPakistan Journal of Medical Sciences, 2020
Objective: This study was aimed to compare the clinical outcomes of ovulation induction (OI) by timed intercourse with letrozole (LTZ) and clomiphene citrate (CC). Methods: Three hundred and twenty-three patients with polycystic ovary syndrome (PCOS) who
M. Sakar, Süleyman Cemil Oğlak
semanticscholar   +1 more source

Effect of Ubiquinol supplementation on ovulation induction in Clomiphene Citrate resistance

open access: yesMiddle East Fertility Society Journal, 2021
Background Clomiphene Citrate is considered the gold-standard for induction of ovulation and has been used for several years to treat PCOS related infertility. Unfortunately, 15-40% of women with PCOS are resistant to Clomiphene Citrate.
Islam Mohamed Magdi Ammar   +1 more
doaj   +1 more source

The Effectiveness of Clomiphene Citrate and Letrozole for Ovulation Induction Related to Endometrial Thickness and Number of Dominant Follicle [PDF]

open access: yes, 2016
The aim of the study is to know the effectiveness of clomiphene citrate and letrozole for ovulationrelated to endometrial thickness and number of dominant follicle. Study design was cross sectional basedon medical records of women who underwent ovulation
Madjid, V. (Veinardi)   +3 more
core   +2 more sources

Does the endometrial thickness on the day of the trigger affect the pregnancy outcomes after fresh cleaved embryo transfer in the clomiphene citrate‐based minimal stimulation cycle?

open access: yesReproductive Medicine and Biology, 2020
Thin endometrium is often observed after clomiphene citrate (CC) administration for follicular development and is one of the reasons for embryo transfer (ET) cancelation or implantation failure.
Seiko Nishihara   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy